Progression of myeloproliferative neoplasm with BCR::JAK2 fusion to acute leukemia of ambiguous lineage-Reference-Cited by-同舟云学术

Progression of myeloproliferative neoplasm with BCR::JAK2 fusion to acute leukemia of ambiguous lineage

Published:2024-02-03 Issue:5 Volume:103 Page:1797-1799
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Suárez Edwin Uriel^ORCID,Piris Miguel Ángel,Rodríguez-Pinilla Socorro María,García Juan F.,López-Lorenzo José Luis,Cornago-Navascués Javier,Salgado-Sánchez Rocío,Castaño-Bonilla Tamara,Mata-Serna Raquel,Alonso-Domínguez Juan M.,Llamas Pilar

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00277-024-05647-6.pdf

Reference16 articles.

1. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R et al (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 36(7):1703–1719. https://doi.org/10.1038/s41375-022-01613-1

2. Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR et al (2022) International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 140(11):1200–1228. https://doi.org/10.1182/blood.2022015850

3. Schwaab J, Knut M, Haferlach C, Metzgeroth G, Horny HP et al (2015) Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes. Ann Hematol 94(2):233–238. https://doi.org/10.1007/s00277-014-2221-y

4. Metzgeroth G, Steiner L, Naumann N, Lübke J, Kreil S et al (2023) Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: reevaluation of the defining characteristics in a registry-based cohort. Leukemia. https://doi.org/10.1038/s41375-023-01958-1

5. He R, Greipp PT, Rangan A, Mai M, Chen D et al (2016) BCR-JAK2 fusion in a myeloproliferative neoplasm with associated eosinophilia. Cancer Genet 209(5):223–228. https://doi.org/10.1016/j.cancergen.2016.03.002